Other Information
−Removed: During the three months ended March 31, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the three months ended June 30, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K .
The exhibits in the accompanying Exhibit Index preceding the signature page are filed or furnished as a part of this report and are incorporated herein by reference.
4 unchanged sentences
10.1 Amendment No.
−Removed: 7 dated March 28 , 202 5 to Loan Documents
+Added: 8 dated April 1 8 , 2025 to Loan Documents
8-K 001-37856 10.1 4/21/2025
+Added: #10.2 Medpace Holdings, Inc.
+Added: 2016 Amended and Restated Incentive Award Plan
+Added: 8-K 001-37856 10.1 5/16/2025
31.1 Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer
11 unchanged sentences
** Furnished herewith.
+Added: # Indicates management contract or compensatory plan.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
2 unchanged sentences
(Principal Financial Officer)
−Removed: April 22, 2025
+Added: July 22, 2025
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.